Furthermore, CYP1A1, ODC1 and MAOB comprise the intersection of TACS targets, metabolic pathway targets and disease-related targets, and dehydrocavidine, tetrahydropalmatine and palmatine are considered as potential active compounds for CCl4-induced liver fibrosis therapy. Here, MAOB is linked to Hepatic fibrosis.